Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT.

Slides:

Advertisements

Similar presentations

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

Advertisements

A Randomized Comparison of Everolimus- Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.

Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Disclosures Runlin Gao has received a research grant

Determinants of Cardiorespiratory Fitness in Men Aged 42 to 60 Years With and Without Cardiovascular Disease Jari Antero Laukkanen, MD, PhD, David Laaksonen,

Severity of Coronary Arterial Stenoses Responsible for Acute Coronary Syndromes Ganesh Manoharan, MD, Argyrios Ntalianis, MD, Olivier Muller, MD, PhD,

Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.

Runlin Gao, M.D. On behalf of ABSORB China Investigators

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis Ashok.

XIENCE V vs TAXUS: Game Over! The Studies are Definitive

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

The Epidemic of the 20th Century: Coronary Heart Disease

Trends in Outcomes of Revascularization for Left Main Coronary Disease or Three- Vessel Disease With the Routine Incorporation of Fractional Flow Reserve.

Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.

American Heart Journal

Frequency of Left Ventricular Thrombus in Patients With Anterior Wall Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention and.

Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial.

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Volume 54, Issue 1, Pages (August 2009)

Meta-Analysis of Three Randomized Trials and Nine Observational Studies Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected.

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Does Diabetes Mellitus Abolish the Beneficial Effect of Primary Coronary Angioplasty on Long-term Risk of Reinfarction After Acute ST-Segment Elevation.

Meta-Analysis of Dietary Glycemic Load and Glycemic Index in Relation to Risk of Coronary Heart Disease Jia-Yi Dong, BSc, Yong-Hong Zhang, MD, PhD, Peiyu.

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the.

Amay Parikh, MD, MBA, MS, Kunal Gupta, MD, MBA, Alan C

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Two-Year Clinical Outcomes After Enhanced External Counterpulsation (EECP) Therapy in Patients With Refractory Angina Pectoris and Left Ventricular Dysfunction.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Laszlo Littmann, MD, PhD The American Journal of Medicine

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

American College of Cardiology Presented by Dr. Stephan Windecker

Standardizing definitions for hybrid coronary revascularization

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.

Dean J. Kereiakes et al. JACC 2017;70:

The Epidemic of the 20th Century: Coronary Heart Disease

Carotid Sinus Massage in Patients with Suspected Acute Myocardial Infarction, Tachycardia, and Left Bundle Branch Block Teddy Weiss, MD, Yair Elitzur,

Laszlo Littmann, MD, PhD The American Journal of Medicine

Kay Lee Park, MD, Robert J. Goldberg, PhD, Frederick A

for the SPIRIT IV Investigators

Presented at ACC 2003 Late Breaking Clinical Trials

Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): Immediate and long-term results Alfredo Rodriguez,

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

Michael A. Weber, MD, George L

for the SPIRIT IV Investigators

Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial Edward.

John P. Vavalle, MD, MHS, Renato D. Lopes, MD, PhD, Anita Y

Gregg W. Stone, MD Columbia University Medical Center

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Presentation transcript:

Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years John K. Forrest, MD, Alexandra J. Lansky, MD, Stephanie M. Meller, BA, Liming Hou, PhD, Poornima Sood, MD, MBA, Robert J. Applegate, MD, John C. Wang, MD, Kimberly A. Skelding, MD, Aakar Shah, MS, Dean J. Kereiakes, MD, Krishnankutty Sudhir, MD, PhD, Ecaterina Cristea, MD, Manejeh Yaqub, MD, Gregg W. Stone, MD American Journal of Cardiology Volume 111, Issue 11, Pages 1580-1586 (June 2013) DOI: 10.1016/j.amjcard.2013.01.330 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 Patient distribution by treatment type (XIENCE V vs Taxus Express2) and side branch information (target lesions with vs without side branches) in the SPIRIT IV trial. American Journal of Cardiology 2013 111, 1580-1586DOI: (10.1016/j.amjcard.2013.01.330) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Time-to-event curves for XIENCE V and Taxus Express2 patients with jailed side branches through 2 years. (A) target lesion failure (TLF), (B) ischemia-driven target lesion revascularization (ID-TLR), (C) target vessel myocardial infarction (TV-MI), and (D) Academic Research Consortium (ARC)–defined stent thrombosis (ST) (definite [def] or probable [prob]). HR = hazard ratio. American Journal of Cardiology 2013 111, 1580-1586DOI: (10.1016/j.amjcard.2013.01.330) Copyright © 2013 Elsevier Inc. Terms and Conditions